Semaglutide for heart failure patients with preserved pumping function
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This Phase 2 trial studies whether semaglutide can improve heart function and related body/heart “metabolic” effects in people with heart failure with preserved ejection fraction. It may help you by improving the heart pressures that build up when you’re active and may reduce harmful strain on the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your BMI is 30 or higher (clinically in the obese range).
- You have heart failure symptoms that are class II, III, or IV (based on symptom severity).
- Your heart pumping strength (LVEF) is at least 50% within the past year.
- You have not been hospitalized for heart failure in the past 30 days.
- You meet at least one specific “pressure/measurement” or recent hospitalization pattern showing heart failure with preserved function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether the drug semaglutide can help people with heart failure who are overweight. It aims to see if the drug improves heart function and symptoms.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.
This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
This study compares different diets to see how they affect “arterial stiffness” (how hard the blood vessels are) in people with obesity who are starting semaglutide for weight management. It may help find a diet approach that improves heart and blood-vessel health while you use semaglutide.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.